Please enter the information you want to find
Hot key words：
Shanghai Bao Pharmaceuticals Co., Ltd. specializes in the industrialization and commercialization of recombinant protein and antibody-based therapeutics. We have established a cGMP-compliant manufacturing facility in Shanghai, covering an area of approximately 63,000 square meters. The facility is designed to include multiple drug substance production lines utilizing mammalian cell expression systems as well as bacterial/yeast expression systems. Additionally, it features production lines for finished dosage forms, including injectable solutions, lyophilized powder injections, and pre-filled syringes.
Since
2011
Clinical trial success rate
66.6
%
R&D investment
33.3
%
In August 2011, Suzhou Kangju Biotechnology Co., Ltd. (“Kangju”) was established in Suzhou Industrial Park, focusing on the development of recombinant enzyme drugs and monoclonal antibodies.
In July 2014, Suzhou Centergene Pharmaceuticals Co., Ltd. (Centergene) was established in Suzhou Industrial Park, focusing on the development of glycoprotein drugs (assisted reproductive product line).
In December 2019, Shanghai Bao Pharmaceuticals Co., Ltd. was established in Luodian Industrial Park, Baoshan District, Shanghai. Bao Pharma integrated Kangju and Centergene to take over existing projects and accelerate their industrialization process in 2020.
Acquired 94 mu (approx. 15.5 acres) of land and a 25,000-square-meter facility at 50 Luoxin Road from Shanghai Jingfeng Pharmaceutical Co., Ltd. in October 2021, enabling Bao Pharma to achieve industrial-scale biopharmaceutical production.
Obtained the “Drug Manufacturing License Type A” issued by the Shanghai Administration of Pharmaceuticals and Medical Devices in December 2022 for the production of therapeutic biological products (recombinant human hyaluronidase for injection).
Obtained the Drug Manufacturing License Type C from the Shanghai Administration of Pharmaceuticals and Medical Devices in May 2023 to manufacture recombinant human follicle-stimulating hormone-CTP fusion protein injection developed by its subsidiary, Centergene.
May 2024 – Bao Pharma's wholly owned subsidiary, Suzhou Centergene, received a Drug Clinical Trial Approval from the CDE for its Recombinant Human Chorionic Gonadotropin Injection.
November 2024 – The CDE included “KJ103 for Injection” on the Breakthrough Therapy Designation list. The proposed indication is desensitization therapy for highly sensitized kidney transplant patients, effectively removing pre-existing HLA antibodies to prevent hyperacute rejection.
In July 2025, the indication of “anti-glomerular basement membrane (anti-GBM) disease” for KJ103 for injection was accepted in the Breakthrough Therapy Designation list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).
In August 2025, the long-acting follicle-stimulating hormone αN01 injection, developed by Bao Pharma’s wholly owned subsidiary Suzhou Centergene, was approved for marketing.
